Improving Response to FLT3 Inhibitors-BCL2 the Rescue?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31515455.
- Also identified by DOI 10.1158/1078-0432.CCR-19-2339.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As single agents, FLT3 inhibitors are active in FLT3-mutated acute myeloid leukemia (AML) therapy but not curative. The BCL2 inhibitor, venetoclax, enhances responses to low intensity AML chemotherapy but its activity is limited by MCL1 upregulation. FLT3 inhibitors downregulate MCL1 and synergize with venetoclax in preclinical AML models.<i>See related article by Ma et al., p. 6815</i>.
Medical subject headings
- Leukemia, Myeloid, Acute